HHT Continuing Education Program for medical professionals
We are excited to announce the launch of the HHT Continuing Education Hub, an online platform through which providers of all specialties can take courses on various HHT topics!
Many medical providers are required to earn a certain amount of credits per year. Now, providers seeking to further their HHT knowledge can receive continuing education credits (CE or CME) when they complete our courses.
Read More
Cure HHT Takes on Capitol Hill
This month, our group of Cure HHT staff, patient advocates, physicians and researchers descended upon Capitol Hill with the mission of shedding light on the importance of protecting and expanding federal funding for HHT. In all, we had 35 appointments with congressional and senatorial office members and staff – including a meeting with Senator Susan Collins. Our advocacy efforts wrapped up with a Congressional Briefing from inside the Capitol Building, where we presented on the impact federal funding can have in changing the trajectory of this disease.
Read More
15th HHT International Scientific Conference
The 15th HHT International Scientific Conference will take place in Mandelieu-la-Napoule, France from October 15-19, 2024. Connect with researchers unraveling the mysteries of HHT mechanisms of disease and discovering potential therapies for patients around the world. Registration is now open! Learn more >>
Read More
Leaving a Lasting Legacy Through Planned Giving
One of the most powerful ways to contribute to Cure HHT’s mission is through planned giving, such including Cure HHT in a will or living trust, establishing a life-income plan, or naming us as a beneficiary in an insurance policy. For those passionate about supporting causes close to their hearts, planned giving offers a powerful opportunity to make a lasting impact for generations to come.
Community members who have remembered Cure HHT in their estate plans join an honorary group we call “The Cornerstone Society,” a membership that signifies our warm appreciation of your lasting contribution.
Read More
Send hearts & kisses this special Rare Disease Month!
February is Rare Disease Month and we want to show our stripes and appreciation on this very special LEAP year! Honor someone special to you who is affected by HHT by participating in our annual Kisses for a Cure tribute celebration from February 14 through February 29 This year, Rare Disease Day® will be celebrated on its official and rarely occurring date, February 29th, which occurs only once every four years!
Dr. Anthony Anzell Presented with $20,000 Research Grant
The University of Pittsburgh’s Dr. Anthony Anzell Presented with $20,000 Research Grant from Uplifting Athletes Dr. Anzell is among 10 rare disease researchers to be awarded a grant at Uplifting…
Read More
Cure HHT Leads Global Breakthrough in Bleeding Standards, Paving the Way for Future HHT Therapies
International Consensus Report Published in the American Journal of Hematology Aims to Transform HHT Research, Treatment, and Clinical Trials
Read More
A History of Pazopanib
There are no FDA-approved therapeutics for the treatment of HHT. Cure HHT sought to change that. In many ways,…
Read More
This Landmark HHT Study Could Shift National Attention
We’re excited to share some truly important news for the HHT community. A major new study done in collaboration…
Read More
Volunteers Needed! Join Cure HHT on Capitol Hill
We are calling upon volunteers to Join us in Washington, DC, for HHT Hill Day and be the voice…
Read More
Cure HHT’s 2024 Impact Report
2024: A Year of Significant Transformation and Progress Every year is a different chapter in our story – each…
Read More
Press Release: Diagonal Therapeutics to Present Data at ASH 2024 Demonstrating the Economic and Clinical Burden of HHT
Diagonal Therapeutics — who has raised $128 million in Series A funding to support their sole project, a curative…
Read More
Press Release: Vaderis Receives FDA Fast Track Designation for Treatment of HHT
The below press release was issued Monday, Nov. 18 by Vaderis Therapeutic, and is substantial news for our community. Cure HHT…
Read More
A Monumental $128 Million Step Forward for HHT Research
Today is a monumental day for HHT. The new biotechnology company, Diagonal Therapeutics, officially launched and we wanted to share more about why this is news you simply can’t miss!
In short, Diagonal’s lead program is focused on developing an innovative treatment not just to alleviate the symptoms of HHT – but using antibodies to reverse the formation of vascular malformations altogether. That’s right, there is now a biotechnology company, backed by $128 million in Series A financing, focused entirely on a curative HHT therapy.
For months, Cure HHT has been collaborating with Diagonal’s management team to help make this day a reality. We have connected them to leading HHT scientists to help them further develop their program, and have spent countless hours meeting with venture capital firms to educate them on the burden of this disease and help Diagonal secure funding to launch.
Read More